Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
NCT03648073Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Jan 2019
- Primary completion
- Feb 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gallium ga 68 dotatate in hepatocellular carcinoma (HCC), sponsored by University of Alabama at Birmingham. Started Jan 2019; status: completed.
02
Drugs
gallium ga 68 dotatate
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03648073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03648073.